Journal of Traumatic Stress
March 31, 2019
Ariel J Lang, Anne Malaktaris, Pollyanna Casmar et al.
50 citations
There is considerable interest in developing complementary and integrative approaches for ameliorating posttraumatic stress disorder (PTSD). Compassion meditation (CM) and loving-kindness meditation appear to offer benefits to individuals with PTSD, including symptom reduction. The present study was a pilot randomized controlled trial of CM for PTSD in veterans. The CM condition, an adaptation...
European Addiction Research
March 21, 2019
I. Menéndez-Miranda, Leticia García-Álvarez, M. García-Portilla et al.
Background: Data on associations between cannabis use and psychopathology, cognition and functional impairment in schizophrenia spectrum disorders (SSD) is controversial. Objectives: To examine the effect of cannabis on psychopathology, cognition and real-world functioning in SSD patients. Method: Naturalistic cross-sectional study, 123 clinically stable SSD outpatients. Assessment: demographic...
Psychopharmacology
March 19, 2019
L. Sayson, Chrislean Jun Botanas, Raly James Perez Custodio et al.
RationaleDepressive syndrome or depression is a debilitating brain disorder affecting numerous people worldwide. Although readily available, current antidepressants have low remission rates and late onset times. Recently, N-methyl-D-aspartate (NMDA) receptor antagonists, like ketamine and methoxetamine (MXE), were found to elicit rapid antidepressant effects. As the search for...
Psychotherapy and Psychosomatics
March 18, 2019
Kurt Stocker, G. Hasler, Matthias Hartmann
5 “I kind of enjoyed the next few hours till dinner. I was still kind of floating on air” (5: 06) (T29). 6 “I had this awkward weight that I carried around me wherever I went (0: 47) ... Literally I had the sensation of this steal armor that I wore my entire life [that] – chunks of it – were falling off (3: 03)” (T16). 7 “I did immediately following the first session – and in the second and in...
bioRxiv (Cold Spring Harbor Laboratory)
March 16, 2019
Diego Quattrone, Laura Ferraro, Giada Tripoli et al.
3 citations
preprint
Abstract Objective The evidence is mixed on whether cannabis use is associated with a particular symptomatology in first episode psychosis (FEP) patients. The authors set out to investigate a) patterns of association between cannabis use and transdiagnostic symptom dimensions; b) whether the extent of use of cannabis contributes to the variation in clinical and subclinical symptom profiles....
Journal of Psychoactive Drugs
March 15, 2019
Jennifer Dore, Brent Turnipseed, Shannon Dwyer et al.
207 citations
Currently, ketamine is the only legal psychedelic medicine available to mental health providers for the treatment of emotional suffering. Over the past several years, ketamine has come into psychiatric use as an intervention for treatment resistant depression (TRD), administered intravenously without a psychotherapeutic component. In these settings, ketamine's psychedelic effects are viewed as...
Journal of Psychoactive Drugs
March 15, 2019
Lisa Jerome, Brad Burge, Richard Doblin et al.
87 citations
Psychedelic plants and fungi have been used in indigenous medicinal traditions for millennia. Modern psychedelic research began when Albert Hofmann first synthesized lysergic acid diethylamide (LSD-25) in 1938. Five years later, became the first person to ingest LSD. Hofmann was unaware of the significance of his actions, and the effects they would set in motion. After a burgeoning period of...
Proceedings of the National Academy of Sciences
March 13, 2019
Panos Zanos, Jaclyn N. Highland, Brent W. Stewart et al.
153 citations
Significance Despite available medications for depression, currently approved antidepressants take months to exert therapeutic effects, and ∼30% of patients remain treatment resistant. In contrast, a single subanesthetic dose of ketamine exerts rapid (within hours) and sustained antidepressant actions. Preclinical studies indicate that the ketamine metabolite ( 2R , 6R )-hydroxynorketamine [(...
Journal of Psychoactive Drugs
March 6, 2019
Ansgar Rougemont-Bücking, Henrik Jungaberle, Milan Scheidegger et al.
6 citations
Differences in mental health (MH) of users of distinct psychoactive substances have been shown. Both substance use (SU) and MH in users are influenced by stressful life events. This study compared MH parameters in distinct groups of substance users and evaluated the impact of stress factors on these outcomes. Data stem from the longitudinal Swiss Cohort Study on Substance Use Risk Factors...
The American Journal of Drug and Alcohol Abuse
March 4, 2019
Elias Dakwar
1 citation
This article refers to:5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety